These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 25520097

  • 1. Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?
    Demir L, Yigit S, Sadullahoglu C, Akyol M, Cokmert S, Kucukzeybek Y, Alacacioglu A, Cakalagaoglu F, Tarhan MO.
    Asian Pac J Cancer Prev; 2014; 15(22):9739-45. PubMed ID: 25520097
    [Abstract] [Full Text] [Related]

  • 2. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The clinicopathological characteristics of 'triple-negative' epithelial ovarian cancer.
    Liu N, Wang X, Sheng X.
    J Clin Pathol; 2010 Mar; 63(3):240-3. PubMed ID: 20203223
    [Abstract] [Full Text] [Related]

  • 5. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB, Aman NA, Koui BS, Koffi KD, Traore ZC, Kouyate M.
    Asian Pac J Cancer Prev; 2016 Mar; 17(4):1973-8. PubMed ID: 27221883
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.
    BMC Cancer; 2015 Mar 18; 15():138. PubMed ID: 25880075
    [Abstract] [Full Text] [Related]

  • 9. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A, Adli M, Eryigit Alkis H, Caglayan D.
    J BUON; 2013 Mar 18; 18(3):619-22. PubMed ID: 24065473
    [Abstract] [Full Text] [Related]

  • 10. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J, Liu XL, Han LZ, Xiao G, Li NL, Deng YN, Yin LC, Ling LJ, Yu XY, Tan CL, Huang XP, Liu LX.
    Asian Pac J Cancer Prev; 2015 Mar 18; 16(2):823-9. PubMed ID: 25684532
    [Abstract] [Full Text] [Related]

  • 11. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, Sehouli J, Braicu EI, Dietel M, Darb-Esfahani S.
    Hum Pathol; 2013 Aug 18; 44(8):1465-71. PubMed ID: 23465277
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
    Ajani MA, Lawan A, Oke T, Khramtsova G, Nwanji I, Salami A, Awolude O, Ebili H, Onwukamuche ME, Sveen E, Yoshimatsu T, Olopade OI.
    Afr Health Sci; 2023 Sep 18; 23(3):236-244. PubMed ID: 38357171
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F.
    Clin Breast Cancer; 2012 Oct 18; 12(5):340-6. PubMed ID: 23040002
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
    Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube ET, Plett H.
    Hum Pathol; 2019 Mar 18; 85():299-308. PubMed ID: 30428389
    [Abstract] [Full Text] [Related]

  • 15. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J, Chen K, Jiang W, Mao K, Li S, Kim MJ, Liu Q, Jacobs LK.
    J Cancer Res Clin Oncol; 2017 Jan 18; 143(1):161-168. PubMed ID: 27704268
    [Abstract] [Full Text] [Related]

  • 16. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA, Sabaa BE, Abdelkhalik D, Mansour H, Melis M, Shaalan W, Farouk M, Malik E, Soliman AA.
    J Cancer Res Clin Oncol; 2016 May 18; 142(5):949-58. PubMed ID: 26762850
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.
    Cancer Chemother Pharmacol; 2012 Feb 18; 69(2):533-46. PubMed ID: 21901395
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.
    Oncol Rep; 2007 Nov 18; 18(5):1051-9. PubMed ID: 17914554
    [Abstract] [Full Text] [Related]

  • 20. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M, Tsuda H, Yoshida M, Shimizu C, Kinoshita T, Tamura K.
    Clin Breast Cancer; 2017 Feb 18; 17(1):41-47. PubMed ID: 27477822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.